Tag: proquad market size

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Proquad Market Size, Value And Growth Trajectory Through 2030

The historic period’s growth stemmed from several key factors, including the expansion of routine childhood vaccination programs, a rise in public health awareness initiatives, the introduction of combination vaccines, an increase in pediatric healthcare infrastructure, and government-backed immunization funding.

Projected growth during the forecast period is propelled by several key factors, including a broadening of global vaccination coverage objectives, increased financial commitments towards developing next-generation vaccines, a heightened emphasis on overseeing immunization compliance, the expansion of public-private partnerships for vaccination, and enhancements in vaccine distribution logistics.

Significant trends expected throughout the forecast period encompass a greater acceptance of combination vaccines, an elevated focus on achieving comprehensive pediatric immunization, the expansion of national immunization initiatives, an intensifying drive towards optimizing cold chain logistics, and advancements in vaccine safety and monitoring frameworks.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=12311753&type=smp&name=Proquad%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Proquad Market Opportunity Drivers: What’s Unlocking New Revenue Potential?

An increase in reported measles and chickenpox cases is projected to fuel the expansion of the proquad market. Measles, a highly transmissible viral infection presenting with fever, cough, and a red rash, along with chickenpox, a contagious illness caused by the Varicella-zoster virus and characterized by an itchy, blister-like rash, are both preventable through vaccination. The resurgence of these preventable conditions stems from factors such as decreasing vaccination coverage, the spread of vaccine-related misinformation, a rise in international travel, and outbreaks occurring in communities with low vaccination rates. Proquad, a combined vaccine targeting measles, mumps, rubella, and varicella (chickenpox), offers protection against these illnesses by conferring immunity via a single dose, thereby diminishing infection risk, containing outbreaks, and providing broad coverage to avert complications linked to measles and chickenpox. As an illustration, the World Health Organization, a non-profit organization based in Switzerland, reported in May 2024 that 56,634 measles cases and four deaths were officially documented across 45 out of 53 countries within the WHO European Region during the initial three months of 2024. Additionally, 41 countries reported 61,070 cases and 13 deaths throughout 2023. Consequently, the increased occurrence of measles and chickenpox is propelling the expansion of the proquad market.

Proquad Market Segmentation And Category Overview

The proquad market covered in this report is segmented –

1) By Indication: Measles, Mumps, Rubella, Varicella

2) By Patient Type: Pediatric Patient, Adult Patient

3) By End User: Healthcare Providers, Pharmacies, Public Health Organization

Proquad Market Innovation Trends Shaping Future Development

Leading companies in the proquad market are concentrating on expanding vaccine administration methods, such as intramuscular (IM) administration, to improve the convenience and consistency of immunization practices. Intramuscular (IM) administration describes the delivery of a vaccine or medication directly into muscle tissue, enabling faster absorption into the bloodstream. For example, in March 2023, Merck & Co. Inc., a US-based pharmaceutical company, secured U.S. Food and Drug Administration (FDA) approval to add an intramuscular (IM) administration option to the U.S. Product Insert (USPI) for its MMRV vaccine family, which includes ProQuad. With this approval, the MMRV family joins other commonly recommended vaccines that can be given intramuscularly. Healthcare professionals in the U.S. now have the choice to administer all routinely recommended injectable pediatric vaccines on the CDC immunization schedule via the same IM route. M-M-R II, VARIVAX, and ProQuad are the sole measles, mumps, rubella, and varicella vaccines approved for IM administration in the U.S. The MMRV family of vaccines is also licensed for IM use in the European Union.

Proquad Market Competitive Analysis Of Leading Industry Participants

Major companies operating in the proquad market are Merck and Co. Inc.

View The Full Proquad Market Report:

https://thebusinessresearchcompany.com/report/proquad-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Proquad Market Regional Distribution: Which Areas Power Market Growth?

North America was the largest region in the proquad market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the proquad market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Proquad Market Size Forecast: How Large Could The Market Become By 2030?

The expansion of routine childhood vaccination programs, the rise in public health awareness campaigns, the accessibility of combination vaccines, improvements in pediatric healthcare infrastructure, and government-funded immunization initiatives have all contributed to the growth observed during the historic period.

The forecast period’s expansion is driven by broader global vaccination coverage goals, higher funding for next-generation vaccine R&D, stronger emphasis on tracking immunization adherence, more public-private collaborations in vaccination initiatives, and enhanced logistics for vaccine distribution. Key trends shaping this period involve greater use of combination vaccines, intensified efforts to boost pediatric immunization rates, widened national immunization campaigns, increased attention to cold chain efficiency, and more robust vaccine safety and surveillance frameworks.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20349&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Proquad Market Growth Factors Supporting Long-Term Expansion

The growing number of measles and chickenpox cases is expected to drive the expansion of the proquad market in the coming years. Measles is a highly contagious viral illness characterized by fever, coughing, and a red rash, which can be prevented through vaccination, whereas chickenpox is an infectious disease caused by the Varicella-zoster virus, presenting as an itchy, blister-like rash and also preventable with a vaccine. The increase in measles and chickenpox cases stems from declining vaccination rates, vaccine misinformation, heightened global travel, and outbreaks among unvaccinated groups, contributing to the resurgence of these preventable infections. Proquad is a combined vaccine targeting measles, mumps, rubella, and varicella (chickenpox) that provides immunity through a single shot, lowering infection risk, controlling disease spread, and offering broad protection to prevent complications from measles and chickenpox. For example, in May 2024, the World Health Organization, a Switzerland-based nonprofit, reported 56,634 measles cases and four deaths across 45 of 53 countries in the WHO European Region during the first quarter of 2024, compared to 61,070 cases and 13 deaths from 41 countries in all of 2023. Thus, the rising incidence of measles and chickenpox is fueling growth in the proquad market.

Proquad Market Driver: Increasing Healthcare Expenditures Driving Market Growth Due To Rising Demand For Advanced Medical Services And Innovative Treatments

Higher healthcare spending is expected to boost the proquad market’s expansion. Healthcare expenditures represent the total funds allocated to health-related services, products, and activities over a given timeframe, measured at the individual, community, national, or global level. These rising costs are fueled by factors such as the growing prevalence of chronic diseases, an aging population, progress in medical technology, and a greater need for sophisticated treatments and healthcare services. Healthcare expenditures support proquad by financing immunization initiatives, improving access, fostering public education, and building the infrastructure and insurance systems necessary for its widespread use and effectiveness. In May 2023, the Office for National Statistics, a UK government agency, noted that healthcare spending in the UK reached approximately $362 billion (£292 billion) in 2023, representing a nominal 5.6% rise, while long-term health and social care spending increased by 2.8% in real terms in 2022. Consequently, rising healthcare expenditure is propelling the proquad market forward.

Proquad Market Segment Analysis And Revenue Opportunities

The proquad market covered in this report is segmented –

1) By Indication: Measles, Mumps, Rubella, Varicella

2) By Patient Type: Pediatric Patient, Adult Patient

3) By End User: Healthcare Providers, Pharmacies, Public Health Organization

Proquad Market Industry Trends Shaping Future Revenue Growth

Companies within the proquad market are prioritizing the expansion of administration methods, specifically intramuscular (IM) delivery, to improve both convenience and consistency in vaccination processes. Intramuscular administration involves injecting a vaccine or medication directly into muscle tissue, which facilitates quicker absorption into the bloodstream. For example, in March 2023, Merck & Co. Inc., a pharmaceutical company headquartered in the United States, obtained approval from the U.S. Food and Drug Administration (FDA) to include an intramuscular administration option in the U.S. Product Insert (USPI) for its MMRV vaccine family, which encompasses ProQuad. This approval allows the MMRV family to align with other widely recommended vaccines that are given intramuscularly. Healthcare providers in the U.S. now have the flexibility to administer all routinely suggested injectable pediatric vaccines listed in the CDC immunization schedule using the same IM route. In the U.S., M-M-R II, VARIVAX, and ProQuad stand as the only measles, mumps, rubella, and varicella vaccines cleared for intramuscular administration. Furthermore, the MMRV vaccine family holds licensure for IM use across the European Union as well.

Proquad Market Leading Players Shaping Industry Direction

Major companies operating in the proquad market are Merck and Co. Inc.

Access The Complete Proquad Market Report:

https://www.thebusinessresearchcompany.com/report/proquad-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Proquad Market Geographic Landscape: Which Region Dominates Industry Growth?

North America was the largest region in the proquad market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the proquad market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Size Is Forecasted For The Proquad Market By 2030 Based On Its 2026 Value?

The historical growth can be linked to the broadening of routine childhood immunization schemes, a rise in public health education campaigns, the provision of multi-vaccine options, advancements in pediatric medical facilities, and governmental financial backing for immunization efforts.

Expected growth during the projected timeframe is linked to several factors, including broader global vaccination objectives, increased financial commitments to developing advanced vaccines, a heightened emphasis on overseeing immunization adherence, the expansion of collaborative vaccination initiatives between public and private sectors, and enhancements in the logistical processes for vaccine distribution.

Significant developments anticipated in the upcoming period encompass a greater uptake of multi-component vaccines, increased attention on achieving high immunization rates for children, the broadening of national vaccination schemes, an intensifying focus on refining cold chain management, and the advancement of systems for vaccine safety and surveillance.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20349&type=smp

Which Growth Drivers Are Expected To Support The Proquad Market Forward?

The increasing occurrence of measles and chickenpox is anticipated to fuel the expansion of the proquad market. Measles is a highly contagious viral infection identified by fever, cough, and a red rash, which can be prevented through vaccination. Chickenpox, conversely, is a contagious illness caused by the Varicella-zoster virus, characterized by an itchy, blister-like rash, and is also preventable with a vaccine. Cases of measles and chickenpox are escalating due to factors such as declining vaccination rates, the spread of misinformation about vaccines, increased global travel, and outbreaks within unvaccinated populations, leading to the resurgence of these preventable diseases. Proquad, a combined vaccine for measles, mumps, rubella, and varicella (chickenpox), offers protection against these diseases by providing immunity through a single dose, thereby reducing the risk of infection, controlling outbreaks, and ensuring comprehensive coverage to prevent complications linked to measles and chickenpox. For instance, the World Health Organization, a non-profit organization based in Switzerland, reported in May 2024 that 56,634 measles cases and four deaths were officially documented across 45 out of 53 countries in the WHO European Region during the first three months of 2024. Throughout 2023, 61,070 cases and 13 deaths were reported by 41 countries. Thus, the increasing incidence of measles and chickenpox is driving the growth of the proquad market.

Which Segment Divisions Form The Structure Of The Proquad Market?

The proquad market covered in this report is segmented –

1) By Indication: Measles, Mumps, Rubella, Varicella

2) By Patient Type: Pediatric Patient, Adult Patient

3) By End User: Healthcare Providers, Pharmacies, Public Health Organization

What Trends Are Influencing The Proquad Market Outlook?

Key companies in the proquad market are prioritizing the expansion of vaccine administration options, such as intramuscular (IM) delivery, to enhance the convenience and consistency of immunization practices. Intramuscular (IM) administration refers to placing a vaccine or medication directly into the muscle tissue, which facilitates faster absorption into the bloodstream. For instance, in March 2023, Merck & Co. Inc., a US-based pharmaceutical company, secured U.S. Food and Drug Administration (FDA) approval for the inclusion of an intramuscular (IM) administration option in the U.S. Product Insert (USPI) for its MMRV vaccine family, which includes ProQuad. With this authorization, the MMRV family now aligns with other commonly advised vaccines that can be administered intramuscularly. Healthcare professionals in the U.S. now have the choice to administer all routinely recommended injectable pediatric vaccines on the CDC immunization schedule via the identical IM route. M-M-R II, VARIVAX, and ProQuad are currently the sole measles, mumps, rubella, and varicella vaccines approved for IM administration in the U.S. The MMRV family of vaccines is also authorized for IM use within the European Union.

Which Organizations Are Involved In The Proquad Market?

Major companies operating in the proquad market are Merck and Co. Inc.

Access The Complete Proquad Market Report:

https://www.thebusinessresearchcompany.com/report/proquad-global-market-report

Which Region Stands As The Largest Contributor To The Proquad Market?

North America was the largest region in the proquad market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the proquad market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Proquad Market During 2026–2030?

Historical growth was driven by the expansion of standard childhood immunization programs, alongside a rise in public health awareness campaigns. Further contributions came from the wider availability of combination vaccines, the development of pediatric healthcare infrastructure, and government-supported funding for immunization efforts.

During the projected timeframe, the anticipated expansion can be linked to several factors, including broader global vaccination coverage objectives, increased financial commitments towards advanced vaccine development, a heightened emphasis on overseeing immunization adherence, the proliferation of public-private collaborations for vaccination initiatives, and enhancements in vaccine supply chain management.

Prominent developments anticipated for the upcoming period encompass a greater uptake of multi-component vaccines, an intensified concentration on vaccinating children, the enlargement of country-specific immunization schemes, an increasing priority placed on maintaining optimal cold chain conditions, and enhanced mechanisms for vaccine safety and surveillance.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20349&type=smp

Which Key Factors Are Driving The Proquad Market Growth?

The increasing occurrence of measles and chickenpox is anticipated to fuel the expansion of the proquad market. Measles is a highly contagious viral infection identified by fever, cough, and a red rash, which can be prevented through vaccination. Chickenpox, conversely, is a contagious illness caused by the Varicella-zoster virus, characterized by an itchy, blister-like rash, and is also preventable with a vaccine. Cases of measles and chickenpox are escalating due to factors such as declining vaccination rates, the spread of misinformation about vaccines, increased global travel, and outbreaks within unvaccinated populations, leading to the resurgence of these preventable diseases. Proquad, a combined vaccine for measles, mumps, rubella, and varicella (chickenpox), offers protection against these diseases by providing immunity through a single dose, thereby reducing the risk of infection, controlling outbreaks, and ensuring comprehensive coverage to prevent complications linked to measles and chickenpox. For instance, the World Health Organization, a non-profit organization based in Switzerland, reported in May 2024 that 56,634 measles cases and four deaths were officially documented across 45 out of 53 countries in the WHO European Region during the first three months of 2024. Throughout 2023, 61,070 cases and 13 deaths were reported by 41 countries. Thus, the increasing incidence of measles and chickenpox is driving the growth of the proquad market.

How Is Segmentation Applied In The Proquad Market Segment Analysis?

The proquad market covered in this report is segmented –

1) By Indication: Measles, Mumps, Rubella, Varicella

2) By Patient Type: Pediatric Patient, Adult Patient

3) By End User: Healthcare Providers, Pharmacies, Public Health Organization

What Trends Are Transforming The Proquad Market?

Leading entities in the ProQuad market are concentrating on broadening vaccine delivery methods, particularly intramuscular (IM) administration, to improve ease of use and uniformity in immunization procedures. IM administration involves injecting a vaccine or medicine straight into muscle tissue, which facilitates quicker absorption into the bloodstream. An example of this is Merck & Co. Inc., a US pharmaceutical firm, which secured U.S. Food and Drug Administration (FDA) clearance in March 2023 to include an intramuscular (IM) administration option in the U.S. Product Insert (USPI) for its MMRV vaccine portfolio, encompassing ProQuad. Following this approval, the MMRV family now aligns with other frequently recommended vaccines suitable for IM delivery. Consequently, medical professionals in the U.S. can now choose to administer all standard injectable pediatric vaccines from the CDC immunization schedule using the identical IM route. Notably, M-M-R II, VARIVAX, and ProQuad stand as the sole measles, mumps, rubella, and varicella vaccines cleared for IM administration within the U.S. Furthermore, the MMRV vaccine range holds licenses for intramuscular application across the European Union.

Who Are The Companies Participating In The Proquad Market Environment?

Major companies operating in the proquad market are Merck and Co. Inc.

Get The Full Proquad Market Report:

https://www.thebusinessresearchcompany.com/report/proquad-global-market-report

Where Is The Proquad Market Primarily Concentrated By Region?

North America was the largest region in the proquad market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the proquad market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Proquad Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/proquad-global-market-report

Browse Through More Reports Similar to the Global Proquad Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Financial Analytics Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-analytics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Proquad Market By The End Of 2030?

The expansion observed over time was primarily due to the wider implementation of routine childhood vaccination programs, increasing public health awareness campaigns, the introduction of combined vaccines, advancements in pediatric healthcare facilities, and government-backed funding for immunizations.

The projected growth during the forecast period is propelled by the broadening of global vaccination coverage objectives, increased capital directed towards the creation of next-generation vaccines, a heightened emphasis on overseeing immunization adherence, the proliferation of public-private collaborations for vaccination, and enhancements in vaccine distribution networks.

Key developments anticipated during the forecast period encompass the greater adoption of combination vaccines, a heightened focus on pediatric immunization rates, the enlargement of national immunization initiatives, an increasing emphasis on optimizing cold chain logistics, and enhancements to vaccine safety and surveillance frameworks.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20349&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Proquad Market?

The increasing occurrence of measles and chickenpox is projected to boost the expansion of the proquad market in the future. Measles, a highly transmissible viral infection presenting with fever, cough, and a red skin rash, can be prevented by vaccination. Similarly, chickenpox is a contagious illness stemming from the Varicella-zoster virus, identifiable by an itchy, blister-like rash, and is also vaccine-preventable. The uptick in measles and chickenpox instances is attributed to reduced vaccination coverage, the spread of inaccurate information regarding vaccines, greater international travel, and occurrences in communities with low vaccination rates, causing these preventable illnesses to reappear. Proquad, a quadrivalent vaccine targeting measles, mumps, rubella, and varicella (chickenpox), offers protection against these conditions by imparting immunity from a single administration, thereby lowering infection risks, managing disease outbreaks, and guaranteeing thorough protection to avert complications linked to measles and chickenpox. As an illustration, in May 2024, the World Health Organization, a non-profit based in Switzerland, documented 56,634 measles cases and four fatalities officially reported across 45 of 53 countries within the WHO European Region during the initial three months of 2024. In 2023, 61,070 cases and 13 deaths were reported by 41 nations. Consequently, the growing prevalence of measles and chickenpox is stimulating the expansion of the proquad market.

Which Segment Classifications Shape The Proquad Market?

The proquad market covered in this report is segmented –

1) By Indication: Measles, Mumps, Rubella, Varicella

2) By Patient Type: Pediatric Patient, Adult Patient

3) By End User: Healthcare Providers, Pharmacies, Public Health Organization

How Are Trends Impacting The Proquad Market?

Leading companies in the proquad market are prioritizing the expansion of vaccine administration options, specifically intramuscular (IM) administration, to enhance the convenience and consistency of immunization practices. Intramuscular (IM) administration involves delivering a vaccine or medication directly into muscle tissue, which facilitates quicker absorption into the bloodstream. For example, in March 2023, Merck & Co. Inc., a US-based pharmaceutical company, obtained U.S. Food and Drug Administration (FDA) approval to add an intramuscular (IM) administration option to the U.S. Product Insert (USPI) for its MMRV vaccine family, which includes ProQuad. Following this approval, the MMRV family now aligns with other commonly recommended vaccines that can be administered intramuscularly. U.S. healthcare professionals are now able to administer all routinely recommended injectable pediatric vaccines on the CDC immunization schedule using the same IM route. M-M-R II, VARIVAX, and ProQuad represent the only measles, mumps, rubella, and varicella vaccines approved for IM administration in the U.S. Additionally, the MMRV family of vaccines is licensed for IM use in the European Union.

Which Companies Are Expanding Their Footprint In The Proquad Market?

Major companies operating in the proquad market are Merck and Co. Inc.

Read the full proquad market report here:

https://www.thebusinessresearchcompany.com/report/proquad-global-market-report

Which Regions Are Projected To Dominate The Proquad Market In The Coming Years?

North America was the largest region in the proquad market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the proquad market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Proquad Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20349&type=smp

Browse Through More Reports Similar to the Global Proquad Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Financial Analytics Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-analytics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the proquad market from 2026–2035 with trusted insights from The Business Research Company

How is the Proquad Market size predicted to change over the forecast window of 2026–2035?

Historically, the growth witnessed can be ascribed to several contributing factors, including the broadening of routine childhood vaccination programs, a rise in public health awareness initiatives, and the enhanced availability of combination vaccines. Additionally, the expansion of pediatric healthcare infrastructure and government-backed immunization funding also played significant roles.

The growth expected in the forecast period can be attributed to several factors, including the broadening of global vaccination reach objectives, escalating financial commitments towards innovative vaccine development, and a heightened scrutiny on adherence to immunization protocols. Additionally, the proliferation of collaborative vaccination initiatives between public and private entities, along with enhancements in vaccine distribution logistics, will contribute to this expansion.

Major trends anticipated during the forecast period encompass a greater uptake of combination vaccines, an intensified emphasis on covering pediatric immunizations, and the enlargement of national immunization schemes. Furthermore, a heightened importance is placed on optimizing the cold chain, alongside the implementation of upgraded systems for vaccine safety and oversight.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20349&type=smp

Which Drivers Are Contributing To The Expansion Of The Proquad Market?

The increasing prevalence of measles and chickenpox is anticipated to drive the expansion of the proquad market. Measles is a highly contagious viral infection characterized by fever, cough, and a red rash, preventable through vaccination, while chickenpox, caused by the Varicella-zoster virus, presents as an itchy blister-like rash and is also vaccine-preventable. The rise in measles and chickenpox cases is attributed to declining vaccination rates, the spread of misinformation about vaccines, increased global travel, and outbreaks within unvaccinated populations, leading to the resurgence of these preventable diseases. Proquad, a combination vaccine for measles, mumps, rubella, and varicella (chickenpox), offers protection against these illnesses by providing immunity with a single dose, thereby lowering the risk of infection, aiding in outbreak control, and ensuring comprehensive coverage to prevent complications associated with measles and chickenpox. For instance, in May 2024, according to the World Health Organization, a Switzerland-based non-profit organization, 56,634 measles cases and four deaths were officially reported across 45 out of 53 countries in the WHO European Region during the first three months of 2024. Throughout 2023, 61,070 cases and 13 deaths were reported by 41 countries. Thus, the escalating incidence of measles and chickenpox is propelling the growth of the proquad market.

What Segment Categories Are Covered In The Proquad Market?

The proquad market covered in this report is segmented –

1) By Indication: Measles, Mumps, Rubella, Varicella

2) By Patient Type: Pediatric Patient, Adult Patient

3) By End User: Healthcare Providers, Pharmacies, Public Health Organization

Which Trends Are Expected To Influence The Proquad Market In The Upcoming Years?

Leading companies in the proquad market are primarily focused on expanding vaccine administration methods, such as intramuscular (IM) administration, to improve the convenience and consistency of immunization practices. Intramuscular (IM) administration entails delivering a vaccine or medication directly into the muscle tissue, which allows for quicker absorption into the bloodstream. For example, in March 2023, Merck & Co. Inc., a US-based pharmaceutical company, obtained U.S. Food and Drug Administration (FDA) approval to add an intramuscular (IM) administration option to the U.S. Product Insert (USPI) for its MMRV vaccine family, including ProQuad. With this approval, the MMRV family now aligns with other commonly recommended vaccines that can be administered intramuscularly. Healthcare professionals in the U.S. can now choose to administer all routinely recommended injectable pediatric vaccines listed in the CDC immunization schedule via the same IM route. M-M-R II, VARIVAX, and ProQuad are the exclusive measles, mumps, rubella, and varicella vaccines approved for IM administration in the U.S. Additionally, the MMRV family of vaccines is licensed for IM use within the European Union.

Which Major Industry Participants Are Leading The Proquad Market Growth?

Major companies operating in the proquad market are Merck and Co. Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/proquad-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Proquad Market?

North America was the largest region in the proquad market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the proquad market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Proquad Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20349&type=smp

Browse Through More Reports Similar to the Global Proquad Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Financial Analytics Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-analytics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Proquad Market Grown from 2024 to 2025?

The market size of Proquad has been experiencing a growth of XX (HCAGR) recently. It’s estimated to escalate from a valuation of $XX million in 2024 to $XX million in 2025, growing at a compounded annual growth rate (CAGR) of XX%. The substantial growth in the previous periods is due to factors such as stable immunization timetables, the benefits of combination vaccines, vaccination initiatives backed by the government, occurrences of epidemics, a robust healthcare system, and regulatory authorizations.

What Growth Rate Is Anticipated for the Proquad Market in the Coming Years?

In the coming years, the proquad market size is anticipated to experience a forecasted compound annual growth rate (FCAGR) of XX%. It is predicted to expand to a value of $XX million in 2029, showcasing a compound annual growth rate (CAGR) of XX%. The prospective growth in this period could be explained by several factors such as population increase, the amplification of healthcare accessibility, worldwide health initiatives, growing cognizance of diseases preventable through vaccination, funds for vaccination from the government, and an increased emphasis on prevention in healthcare. Over the forecast period, major trends to note include global coverage of vaccination, progression in technology for vaccine delivery, the incorporation of vaccines into regular health systems, advancements in vaccine accessibility, and heightened consciousness about vaccine safety.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20349&type=smp

Who Are the Leading Companies in the Proquad Market?

Major companies operating in the proquad market are Merck and Co. Inc.

What Are the Key Drivers of the Proquad Market?

The escalating rates of measles and chickenpox are projected to fuel the expansion of the proquad market in the future. Measles, a highly communicable viral infection marked by fever, cough, and a red rash, can be avoided with vaccination, much like chickenpox, a contagious condition triggered by the Varicella-zoster virus, distinguished by an itch-inducing blister-like rash, also preventable through vaccination. The proliferation of measles and chickenpox incidents can be attributed to falling vaccination rates, vaccine misinformation, increased international travel, and occurrences in populations that are not vaccinated, resulting in the resurgence of these avoidable diseases. Proquad, a mixed vaccine for measles, mumps, rubella, and varicella (chickenpox), offer protection against these diseases by stimulating immunity with a single dose, lowering the probability of infection, managing outbreaks, and securing comprehensive protection to avoid complications associated with measles and chickenpox. The World Health Organization, a non-profit organization based in Switzerland, reported in May 2024, that there were 56,634 measles cases and four casualties officially reported from 45 out of 53 countries in the WHO European Region during the initial three months of 2024. During 2023, a total of 61,070 cases and 13 deaths were reported by 41 countries. Thus, the growing occurrence of measles and chickenpox is pushing the advancement of the proquad market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20349&type=smp

What Are the Key Market Segments in the Proquad Industry?

The proquad market covered in this report is segmented –

1) By Indication: Measles; Mumps; Rubella; Varicella

2) By Patient Type: Pediatric Patient; Adult Patient

3) By End User: Healthcare Providers; Pharmacies; Public Health Organization

What Are the Latest Trends in the Proquad Market?

One significant trend witnessed in the proquad market is the emphasis on broadening the range of vaccine delivery options, such as intramuscular (IM) administration, to improve convenience and uniformity in immunization procedures. Intramuscular (IM) administration implies directly injecting a vaccine or medication into the muscle tissue, which facilitates quicker absorption into the bloodstream. For example, in March 2023, the United States pharmaceutical company, Merck & Co. Inc., was granted approval by the U.S. Food and Drug Administration (FDA) to add an intramuscular (IM) administration alternative to the U.S. Product Insert (USPI) for their MMRV vaccine range, ProQuad included. This approval means that MMRV vaccines are now included in the list of frequently recommended vaccines which can be administered intramuscularly. The medical professionals in the U.S. now have an option to administer all routinely recommended injectable pediatric vaccines in the CDC immunization schedule through the same IM method. M-M-R II, VARIVAX, and ProQuad are the sole vaccines for measles, mumps, rubella, and varicella, which are approved for IM administration in the U.S. Furthermore, The MMRV vaccine range is also licensed for IM usage in the European Union.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/proquad-global-market-report

What Are the Key Regional Markets in the Proquad Industry?

North America was the largest region in the proquad market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the proquad market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20349

This Report Delivers Insight On:

1. How big is the proquad market, and how is it changing globally?

2. Who are the major companies in the proquad market, and how are they performing?

3. What are the key opportunities and risks in the proquad market right now?

4. Which products or customer segments are growing the most in the proquad market?

5. What factors are helping or slowing down the growth of the proquad market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the proquad market grown in recent years?

In the past few years, the market size for Proquad has seen a XX (HCAGR) boom. Predictions show the growth from $XX million in 2024, scaling up to $XX million in 2025 with a Compound Annual Growth Rate (CAGR) of XX%. This progress in the historic period is associated with structured immunization timelines, the benefits of combination vaccines, vaccination schemes aided by the government, outbreaks of epidemics, a robust healthcare system, and regulatory endorsements.

How is the proquad market size expected to evolve during the forecast period?

In the coming years, the proquad market is projected to witness a compound annual growth rate (CAGR) of XX%, raising its value to $XX million by 2029. The anticipated growth during the forecast period is largely driven by increasing population, better access to healthcare services, worldwide health initiatives, heightened recognition of diseases that can be prevented through vaccination, governmental funding for vaccination, and a heightened emphasis on preventive healthcare. The forecast period is characterized by trends such as global vaccine coverage, advancements in vaccine delivery technology, the inclusion of vaccines in ordinary health regimes, an enhancement in vaccine accessibility, and a rise in vaccine safety awareness.

Get your proquad market report here!

https://www.thebusinessresearchcompany.com/report/proquad-global-market-report

Which key drivers are propelling the proquad market’s growth?

The escalating rates of measles and chickenpox are projected to boost the expansion of the proquad market. Measles is mostly represented by symptoms like high fever, cough, and red rash, and this extremely infectious disease can be avoided with immunization. Similarly, chickenpox, an infectious disease that results in itchy blister-like rashes, can also be prevented by vaccination and is caused by the Varicella-zoster virus. Lower vaccination rates, misconceptions about vaccines, increased international travel, and outbreaks among unvaccinated groups, have led to a surge in cases of these otherwise preventable diseases. Proquad offers an effective solution with a combination vaccine for measles, mumps, rubella, and chickenpox (varicella), which offers protection from these conditions through a single dose, lessening the likelihood of infection, managing outbreaks, and providing well-rounded coverage to prevent complications relating to measles and chickenpox. For example, as per the World Health Organization, a non-profit organization based in Switzerland, 56,634 cases of measles were officially recorded across 45 out of 53 countries within the WHO European Region during the first three months of 2024 along with four fatalities. Over 2023, there were 61,070 cases and 13 deaths reported across 41 countries. Consequently, the elevated incidence of measles and chickenpox is stimulating the growth of the proquad market.

What are the market segments in the proquad industry?

The proquad market covered in this report is segmented –

1) By Indication: Measles; Mumps; Rubella; Varicella

2) By Patient Type: Pediatric Patient; Adult Patient

3) By End User: Healthcare Providers; Pharmacies; Public Health Organization

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20349&type=smp

Which leading companies are shaping the growth of the proquad market?

Major companies operating in the proquad market are Merck and Co. Inc.

What key trends are currently impacting the proquad market’s development?

The proquad market is trending towards enlarging the range of vaccine administration methods, with a focus on intramuscular (IM) injections, in order to advance both convenience and uniformity in immunization protocols. IM administration is a method that injects vaccines or medications directly into the muscle tissue for quicker absorption into the bloodstream. For example, in March 2023, the U.S. based pharmaceutical firm, Merck & Co. Inc., was greenlighted by the U.S. Food and Drug Administration (FDA) to include an IM administration option in the U.S. Product Insert (USPI) for its MMRV vaccine lineup, which includes ProQuad. This authorization means that the MMRV vaccine lineup now aligns with other frequently recommended vaccines that are administered intramuscularly. U.S. healthcare professionals can now opt to administer all conventionally recommended injectable pediatric vaccines in the CDC immunization schedule through the same IM method. The trio of M-M-R II, VARIVAX, and ProQuad are the only authorized IM vaccines for measles, mumps, rubella, and varicella in the U.S. The MMRV vaccine lineup is also licensed for IM use in the European Union.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20349

Which geographic areas are influencing the growth of the proquad market?

North America was the largest region in the proquad market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the proquad market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Autoimmune Disease Diagnosis Global Market Report 2025

https://thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Hepatitis B Virus (HBV) Global Market Report 2025

https://thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report

Global Drug Delivery Devices Opportunities And Strategies Global Market Report 2025

https://thebusinessresearchcompany.com/report/drug-delivery-devices-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: